The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers
Uro-Oncology
Related content
Uro-Oncology
Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe
Eur Urol
Vynckier P, Annemans L, Raes S, Amrouch C, Lindgren P, Májek O, Beyer K, Leenen RCA, Venderbos LDF, Denijs F, van Harten MJ, Helleman J, Chloupková R, Briers E, Vasilyeva V, Rivas JG, Basu P, Chandran A, van den Bergh RCN, Collen S, Van Poppel H, Roobol MJ, members of the PRAISE-U Consortium
doi: 10.1016/j.eururo.2024.04.036
Uro-Oncology
Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial
Eur Urol
Krilaviciute A, Kaaks R, Seibold P, de Vrieze M, Lakes J, Radtke JP, Kuczyk M, Harke NN, Debus J, Fink CA, Herkommer K, Gschwend JE, Meissner VH, Benner A, Kristiansen G, Hadaschik B, Arsov C, Schimmöller L, Antoch G, Giesel FL, Makowski M, Wacker F, Schlemmer HP, Becker N, Albers P
doi: 10.1016/j.eururo.2024.04.030
Uro-Oncology
Impact of Intraoperative Opioid Use and a Combined Anesthesia Regimen in Patients Undergoing Radical Prostatectomy for Prostate Cancer in a Single-Center Cohort
J Clin Med
Marcon J, Bischoff R, Rattenhuber K, Chaloupka M, Askari D, Jokisch JF, Becker AJ, Pfitzinger PL, Keller P, Berg E, Stief CG, Siegl D, Kowalski C, Buchner A, Pyrgidis N, Weinhold P
doi: 10.3390/jcm13247506
Uro-Oncology
Prostate cancer detection and complications of MRI-targeted prostate biopsy using cognitive registration, software-assisted image fusion or in-bore guidance: a systematic review and meta-analysis of comparative studies
Prostate Cancer Prostatic Dis
Falagario UG, Pellegrino F, Fanelli A, Guzzi F, Bartoletti R, Cash H, Pavlovich C, Emberton M, Carrieri G, Giannarini G
doi: 10.1038/s41391-024-00827-x
Uro-Oncology
The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy-naive patients, according to the localization of the lesion at the mpMRI: A single-center retrospective observational study
Prostate
Massanova M, Barone B, Caputo VF, Napolitano L, Ponsiglione A, Del Giudice F, Ferro M, Lucarelli G, Lasorsa F, Busetto GM, Robertson S, Trama F, Imbimbo C, Crocetto F
doi: 10.1002/pros.24761
HPV and Gynecologic Cancer
Evidence of decreased long-term risk of cervical pre-cancer after negative primary HPV screens compared to negative cytology screens in a longitudinal cohort study
Cancer Epidemiol Biomarkers Prev
Gottschlich A, Hong Q, Gondara L, Alam MS, Cook DA, Martin RE, Lee M, Melinikow J, Peacock S, Proctor L, Stuart G, Franco EL, Krajden M, Smith LW, Ogilvie GS
doi: 10.1158/1055-9965.EPI-23-1587
Uro-Oncology
Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience
Prostate
Losee M, Kavanaugh M, Liu M, Borges N, Haberman V, Ritzer J, Wolanski A, Bhimaniya S, Choudhury AD, Hyun H, Stoltenberg H, Kilbridge KL, Morgans A, Pomerantz M, Robertson M, Sakellis C, Shah H, Taplin ME, Wei XX, Ng T, Ravi P, Jacene H
doi: 10.1002/pros.24880
Uro-OncologyFurther Publications Urology
Detection of clinically significant prostate cancer following initial omission of biopsy in multiparametric MRI era
Prostate Cancer Prostatic Dis
Li EV, Busza AM, Siddiqui MR, Aguiar JA, Keeter MK, Neill C, Kumar SK, Mi X, Schaeffer EM, Patel HD, Ross AE
doi: 10.1038/s41391-024-00853-9
COMMENTED
Uro-Oncology
Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
JAMA Oncol
Tilki D, Chen MH, Wu J, Huland H, Graefen M, Trock BJ, Han M, D'Amico AV
doi: 10.1001/jamaoncol.2025.0110